Individuals with BARD1 and BRCA1 germline pathogenic mutations have been found to have a higher incidence rates of aggressive breast cancer phenotypes, such as TNBCs, which are associated with higher rates of recurrence, progression, and mortality [31,32,33]. This evidence concerns the gene BARD1 and breast carcinoma.